Literature DB >> 20528455

Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Xiaowei Dong1, Russell J Mumper.   

Abstract

Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.

Entities:  

Mesh:

Year:  2010        PMID: 20528455      PMCID: PMC2925023          DOI: 10.2217/nnm.10.35

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  161 in total

Review 1.  Interstitial-lymphatic mechanisms in the control of extracellular fluid volume.

Authors:  K Aukland; R K Reed
Journal:  Physiol Rev       Date:  1993-01       Impact factor: 37.312

Review 2.  Clinical significance of P-glycoprotein in multidrug resistance malignancies.

Authors:  R J Arceci
Journal:  Blood       Date:  1993-05-01       Impact factor: 22.113

3.  Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.

Authors:  K A Gelmon; J Latreille; A Tolcher; L Génier; B Fisher; D Forand; S D'Aloisio; L Vernillet; L Daigneault; A Lebecq; M Besenval; E Eisenhauer
Journal:  J Clin Oncol       Date:  2000-12-15       Impact factor: 44.544

4.  Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake.

Authors:  H Carrstensen; R H Müller; B W Müller
Journal:  Clin Nutr       Date:  1992-10       Impact factor: 7.324

5.  Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells.

Authors:  Elena V Batrakova; Shu Li; Valery Yu Alakhov; Donald W Miller; Alexander V Kabanov
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

6.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy.

Authors:  Y Boucher; L T Baxter; R K Jain
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

7.  Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells.

Authors:  David Sadava; Aaron Coleman; Susan E Kane
Journal:  J Liposome Res       Date:  2002-11       Impact factor: 3.648

8.  Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.

Authors:  D R Bell; J H Gerlach; N Kartner; R N Buick; V Ling
Journal:  J Clin Oncol       Date:  1985-03       Impact factor: 44.544

9.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

Authors:  Yogesh B Patil; Suresh K Swaminathan; Tanmoy Sadhukha; Linan Ma; Jayanth Panyam
Journal:  Biomaterials       Date:  2009-10-01       Impact factor: 12.479

10.  Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

Authors:  Maha Saad; Olga B Garbuzenko; Tamara Minko
Journal:  Nanomedicine (Lond)       Date:  2008-12       Impact factor: 5.307

View more
  74 in total

Review 1.  Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.

Authors:  William C Zamboni; Vladimir Torchilin; Anil K Patri; Jeff Hrkach; Stephen Stern; Robert Lee; Andre Nel; Nicholas J Panaro; Piotr Grodzinski
Journal:  Clin Cancer Res       Date:  2012-06-05       Impact factor: 12.531

2.  Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro.

Authors:  Forrest M Kievit; Freddy Y Wang; Chen Fang; Hyejung Mok; Kui Wang; John R Silber; Richard G Ellenbogen; Miqin Zhang
Journal:  J Control Release       Date:  2011-01-26       Impact factor: 9.776

3.  Block copolymer micelles with acid-labile ortho ester side-chains: Synthesis, characterization, and enhanced drug delivery to human glioma cells.

Authors:  Rupei Tang; Weihang Ji; David Panus; R Noelle Palumbo; Chun Wang
Journal:  J Control Release       Date:  2010-12-29       Impact factor: 9.776

Review 4.  Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.

Authors:  Sophie Marchal; Amélie El Hor; Marie Millard; Véronique Gillon; Lina Bezdetnaya
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

Review 5.  Nanomedicine therapeutic approaches to overcome cancer drug resistance.

Authors:  Janet L Markman; Arthur Rekechenetskiy; Eggehard Holler; Julia Y Ljubimova
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

6.  Effect of five novel 5-substituted tetrandrine derivatives on P-glycoprotein-mediated inhibition and transport in Caco-2 cells.

Authors:  Zhonglian Cao; Dan Li; Li Liu; Ping Yang
Journal:  Oncol Lett       Date:  2018-09-24       Impact factor: 2.967

Review 7.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

Review 8.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

Review 9.  PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.

Authors:  Zahid Hussain; Shahzeb Khan; Muhammad Imran; Muhammad Sohail; Syed Wadood Ali Shah; Marcel de Matas
Journal:  Drug Deliv Transl Res       Date:  2019-06       Impact factor: 4.617

10.  Special AT-rich sequence binding protein 1 regulates the multidrug resistance and invasion of human gastric cancer cells.

Authors:  Fuqiang Sun; Xiaoming Lu; Hang Li; Zhao Peng; Ke Wu; Guobin Wang; Qiang Tong
Journal:  Oncol Lett       Date:  2012-04-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.